Vivos Inc to Present at The LD 500 Virtual Conference
Vivos Inc (RDGL) has announced its participation in the LD 500 investor conference, scheduled for September 3, 2020, at 1:40 PM PST. Dr. Mike Korenko, CEO, will present virtually, emphasizing the accessibility of this event amid COVID-19 restrictions. The conference runs from September 1 to 4, offering a platform for unique companies in the microcap space. Vivos specializes in an Yttrium-90 based injectable brachytherapy device for treating tumors in humans and animals, utilizing proprietary hydrogel technology for targeted radiation treatment.
- None.
- None.
LOS ANGELES, CA / ACCESSWIRE / September 1, 2020 / Vivos Inc (OTCQB:RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals and in humans, today announced that it will be presenting at the LD 500 investor conference on Thursday September 3 at 1:40 PST / 4:00 PM EST. Dr. Mike Korenko (CEO of Vivos Inc) will be presenting to a live virtual audience.
Register here: https://ld500.ldmicro.com/
"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space." stated Chris Lahiji, Founder of LD.
The LD 500 will take place on September 1st through the 4th.
View Vivos Inc's profile here: http://www.RadioGel.com
Profiles powered by LD Micro - News Compliments of Accesswire
About Vivos Inc
Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet®) and in humans (Radiogel™) that delivers highly localized radiation to destroy cancerous tumors by placing the cancer killing isotope directly inside the treatment area using the company's proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor, without the side effects of treatment that characterize external-beam radiation therapy. Vivos maintains domestic and international trademark and patent protection for Isopet® and Radiogel™.
About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.
What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.
The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.
Contact:
Name: Dr. Mike Korenko
Phone: 509 551 9281
Address: 719 Jadwin Ave; Richland WA 99352
Email: mkorenko@RadioGel.com
SOURCE: Vivos Inc via LD Micro
View source version on accesswire.com:
https://www.accesswire.com/604184/Vivos-Inc-to-Present-at-The-LD-500-Virtual-Conference
FAQ
When is Vivos Inc presenting at the LD 500 investor conference?
What is the focus of Vivos Inc's presentation at the conference?
What dates does the LD 500 conference take place?
Who will present on behalf of Vivos Inc at the LD 500?
What technology does Vivos Inc use for treating tumors?
